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Background: Spinal cord injury (SCI) leads to a profound muscular atrophy, bone loss and bone fragility. While
there is evidence that exercising paralysed muscles may lead to reversal of muscle atrophy in the chronic period
after SCI, there is little evidence that exercise can prevent muscle changes early after injury. Moreover, whether
exercise can prevent bone loss and microarchitectural decay is not clear.
Methods/Design: A multi-centre, parallel group, assessor-blinded randomised controlled trial will be conducted.
Fifty participants with acute spinal cord injury will be recruited from four SCI units in Australia and New Zealand.
Participants will be stratified by site and AIS status and randomised to an experimental or control group. Experimental
participants will receive a 12-week programme of functional electrical stimulation (FES)-assisted cycling. Control
participants will receive a 12-week programme of passive cycling. The primary outcome is muscle cross-sectional area
of the thigh and calf measured using magnetic resonance images (MRI) of the leg. Secondary outcomes include serum
biomarkers of SCI osteoporosis (sclerostin, P1NP and β-CTX), markers of immune function (IL-6, IL-10, FGF2, INF-γ,
TNF-α), neurological function, body composition, depression and quality of life. Leg MRIs will be measured by a single
blinded assessor based in Melbourne. Serum samples will be analysed in a central laboratory. All other characteristics
will be measured at baseline and 12 weeks by blinded and trained assessors at each site. The first participant was
randomised on 27 November 2012.
Discussion: The results of this trial will determine the relative effectiveness of a 12-week programme of FES-assisted
cycling versus passive cycling in preventing muscle atrophy and maintaining skeletal integrity after spinal cord injury.
Trial registration: ACTRN12611001079932 (18 October 2011)
Keywords: Spinal cord injury, Randomised controlled trial, Early exercise, FES cycling, Passive cycling, Muscle atrophy,
Biomarkers, Osteoporosis, Neurological function, Immune function, Quality of lifeBackground
Spinal cord injury (SCI) leads to a profound muscular
atrophy, bone loss and bone fragility [1-3]. Fractures lead
to a marked deterioration in bone quality, and compro-
mise rehabilitation and quality of life [4].
Furthermore, recent advances have identified mecha-
nisms that link muscle and bone metabolism, thereby
identifying such tissues as endocrine organs [5,6]. The
discovery that muscle-secreted factors contribute to
osteocyte viability [7] suggests a link between disuse and
endocrine functions of bone and between muscle endo-
crine action and susceptibility for chronic disease [8,9].* Correspondence: m.galea@unimelb.edu.au
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unless otherwise stated.Such developments have highlighted inter-relationships
between the aetiologies of sarcopenia and osteopenia [10],
cardinal features of secondary disuse disorder such as
occurs after SCI [11,12]. Recognition that SCI involves an
‘endocrine syndrome’ [13,14] has advanced our under-
standing of regulatory mechanisms that contribute to
the clinical features of this catastrophic injury. Given
that muscle-secreted factors (myokines) have endocrine
and other actions, the role of skeletal muscle contrac-
tion induced by exercise following SCI warrants closer
attention.
Thigh girth reduces by 50% within 3 weeks of SCI [15];
thickness of muscle bulk, measured using ultrasound,
reduces by 40% in the first month [16]. A magnetic reson-
ance imaging (MRI) study of changes in muscle cross-his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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showed that the mean CSA of the quadriceps, hamstring
and adductor muscle groups declined by 16%, 14% and
16% respectively [17].
Muscle is a dynamic tissue capable of adapting its
morphology depending on the functional demands placed
on it. There is evidence that exercising paralysed muscles
through functional electrical stimulation (FES)-assisted
cycling leads to reversal of atrophy [18]. Furthermore, in
rats with spinal transection, passive exercise in the form of
pedaling on a motor-driven cycle results in activation of
muscle satellite cells and reversal of hindlimb muscle at-
rophy. This effect is more marked in muscles with slow
oxidative fibres such as soleus [19].
It is still unknown whether unloading of the bones in
the paralysed extremities is the only factor causing rapid
bone loss below the level of injury, or if other factors
such as neuronal, humoral and vascular adaptations after
a SCI are also involved [20,21]. Muscle forces create the
peak forces acting on bone, a relationship summarised
by the mechanostat theory [22], which predicts that
bone mass, strength and size will respond to increasing
muscle maximal forces during bone growth, or the loading
of mature bone. Unloading through disuse or immobilisa-
tion will have a negative effect on bone mass and strength,
both through muscle atrophy and local regulators of cell
phenotype, within the bone tissue microenvironment.
Sclerostin, encoded by the sost gene, is a Wingless-Int
(Wnt) signalling pathway antagonist secreted by osteo-
cytes and is a potent inhibitor of bone formation [23].
Compared to other bone-related proteins, sclerostin is
considered a candidate biomarker for SCI-induced osteo-
porosis [24]. Sclerostin is increased by unloading and sup-
pressed by loading, a feature observed at least in the first
few years after SCI [25,26]. In addition to the mechanical
loading of bone through muscle contraction, muscle myo-
kines released from contracting muscles may protect oste-
ocytes from undergoing cell death [27].
One study has used FES early after injury to prevent
muscle changes rather than reverse them when losses
are well advanced. Baldi et al. [12] compared FES-assisted
cycling with FES-induced isometric muscle contractions
commencing within the first 12 to 15 weeks of injury.
Control subjects who had had no exercise lost 21 to 27%
of muscle mass. FES-cycling, but not FES-induced isomet-
ric exercise, prevented loss of lower limb lean body mass
and gluteal lean body mass at both 3 and 6 months.
Whether exercise can prevent bone loss and micro-
architectural decay or reverse it when established is not
clear. A regimen of FES-assisted isotonic contractions
instituted early after SCI did not lead to an osteogenic
effect in the lower limbs, measured using dual energy
X-ray absorptiometry [28]. A 2010 systematic review [29]
has concluded that FES-cycling does not improve ormaintain bone at the tibial diaphysis in the acute phase,
but may increase/maintain lower extremity bone mineral
density (BMD) in the chronic phase after SCI [30], the
implication being that site-specific bone adaptation is both
time- and dose-dependent and thus, mechanisms of bone
adaptation may differ in acute and in established SCI.
In this trial, we will provide an exercise programme
that involves FES-cycling against increasing loads as
early as practicable after SCI, commencing when the
individual is still confined to bed. We hypothesise that
muscle activation will prevent muscle atrophy. In addition,
we hypothesise that mechanical strains associated with
loading and changing leg position during cycling will in-
hibit sclerostin levels and thereby preserve skeletal struc-
ture by reducing inhibition of bone formation and reduce
increased bone resorption at the cellular level seen early
after injury.Methods
The trial was registered on the Australian and New
Zealand Clinical Trials Registry (ACTRN12611001079932)
on 18 October 2011. The first participant was randomised
on 27 November 2012, and the final participant on 31
March 2014.Funding
The study is being funded by the Transport Accident
Commission (Victorian Neurotrauma Initiative), and the
National Health and Medical Research Council of
Australia. At the conclusion of the trial, all equipment
purchased for the trial will be gifted to the participating
hospitals.Design
A multi-centre, assessor-blinded, randomised controlled
trial will be conducted. Experimental group participants
will undertake an intensive 12-week programme of FES-
assisted cycling, while control group participants will
undertake a passive cycling programme over the same
period. The trial will be conducted in four spinal units
in Australia and New Zealand. Ethical approval has been
obtained from the Human Research Ethics Committees
at Austin Health in Melbourne (H2012/04476), Royal
Perth Hospital in Perth (EC 2012/080), Princess Alexan-
dra Hospital in Brisbane (HREC/12/QPAH/085) and the
Multi-region Ethics Committee in New Zealand (MEC/
12/02/020) and at the University of Melbourne (Trial
Sponsor, HREC 1237599). Participants will be provided
with information sheets and written informed consent will
be obtained prior to recruitment and baseline assessment.
See Table 1 for the schedule of enrolment, interventions,
and assessments.
Table 1 Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) checklist: schedule of enrolment,
interventions, and assessments
Enrolment Allocation Intervention Post-intervention










Muscle cross-sectional area of thigh and calf (1° outcome measure) X X
Serum sclerostin X X
Other serum biomarkers X X
Muscle mass X X
ISNCSCI Motor and Sensory Scores X X
Depression (HADS) X X
Quality of Life X X
(HUI3, AQoL, WHOQoL-Bref)
*1-week window allowed for assessments.
FES = functional electrical stimulation; ISNCSCI = International Standard for Neurological Classification of Spinal Cord Injury; HADS = Hospital Anxiety and
Depression Scale; HUI3 = Health Utilities Index Mark 3; AQoL = Assessment of Quality of Life; WHOQoL-Bref = WHO Quality of Life-Bref.
Galea et al. Trials 2015, 16:7 Page 3 of 8
http://www.trialsjournal.com/content/16/1/7Participants
Fifty participants with new acute SCI admitted to one of
the four trial sites will be recruited.
Inclusion criteria
Participants will be included if they:
1. Have sustained a complete or incomplete SCI above
T12 no more than 3 weeks previously
2. Have undergone internal fixation of their spinal
fracture or whose fracture is considered sufficiently
stable
3. Are medically stable
4. Are able to provide informed consent
5. Have medical and surgical clearance to participate
in the study
Exclusion criteria
1. Under 18 years of age
2. American Spinal Injury Association Impairment
Scale (AIS) D (50% of the muscles below the injury
level are scored as 3 or above) at baseline
3. In halo or other traction
4. In the ICU
5. Pressure ulcers
6. Peripheral nerve lesion7. Long bone or pelvic fracture
8. Lower limb amputation
9. Metabolic bone disease, including lytic or renal bone
disease, or senile osteoporosis
10.Exposure to drugs that affect bone metabolism
(amino-bisphosphonate, high-dose glucocorticoids,
cyclosporine, anti-epileptic drugs (AEDs))
11.Known contraindications to FES (cardiac pacemaker,
epilepsy, pregnancy)
12.Any other contraindications to participating in
exercise programmes, or outcome assessments, as
advised by the treating physician
13.English language competency insufficient to
understand research procedures and provide
informed consent.
Randomisation
Participants will be randomly assigned to either the ex-
perimental or control group with a 1:1 allocation as per
a computer-generated randomisation schedule stratified
by participating site and injury status (AIS) A/B or AIS C).
The randomisation schedule will be under the control
of a central randomisation unit, independent of the trial,
located at Neuroscience Trials Australia in Melbourne.
A participant will be considered to have entered the
trial once his/her randomisation is revealed to the site
coordinator.
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All participants will attend the assigned exercise pro-
gramme for 48 sessions over 12 weeks, with an intended
frequency of 4 times weekly.
Experimental group
Participants in the experimental group will receive FES-
assisted cycling using a Hasomed RehaStim FES Unit
attached to a MOTOmed cycle (Hasomed GmbH,
Magdeburg, Germany) while they are confined to bed,
and an RT300 cycle (Restorative Therapies, Baltimore,
MD, USA) when they are able to sit in a chair. Surface
electrodes will be applied over the belly of the quadriceps,
gluteal, and hamstrings muscles according to a standar-
dised protocol [31]. The pedal cadence will be set to 15 to
50 rev.min−1 Stimulation intensity will be gradually in-
creased to a maximum of 140 mA with a pulse width of
0.3 ms at a frequency of 35 Hz [31,32]. Participants will
exercise at the maximal power output possible at their
level of recovery. Therapists will evaluate the degree of
muscle contraction, power output and fatigue, and adjust
settings appropriately to maximise time, intensity, and
power of training with a principle of overloading the
muscle. When fatigue occurs, cycling can be stopped and
then re-commenced after a 5-minute break if muscle con-
traction can be re-elicited. For participants with some
degree of volitional muscle activity, the settings will be
adjusted to ensure that resistance is maintained.
Participants will undertake 30 minutes of cycling on
4 days/week for 12 weeks, initially in intermittent pe-
riods of exercise with rest breaks, but progressing to a
maximum of 60 minutes as deemed appropriate by the
supervising therapist/assistant. This can be undertaken
as a single session or split into two sessions, depending
on the participant’s performance and the availability
of staff. All aspects of each training session will be
recorded.
Comparator group
Participants allocated to this group will undertake up to
60 minutes passive cycling on 4 days/week for 12 weeks at
identical pedal cadence to the Experimental Group. Simi-
lar to the Experimental Group, cycling while the partici-
pant is confined to bed will be with the MOTOmed Letto
device (Hasomed GmbH, Magdeburg, Germany) and,
once mobilised into a wheelchair, may use the RT300
cycle (Restorative Therapies, Baltimore, MD, USA) but
without FES-evoked contractions.
Follow-up period
All participants will complete a post-intervention visit at
the end of the 12-week intervention period. Assessments
completed at baseline will be repeated. A follow-up phonecall will be made 1 month after this visit to check on
progress or adverse events in the intervening period.
Quality assurance
To ensure that treatments are of a high standard and
delivered in accordance with the trial protocol, therapists
responsible for administration of the exercise programmes
will attend workshops where they will be trained in the
delivery of the treatment programme and in assessment
procedures. Therapists will also be provided with a written
protocol and standardised case report forms for documen-
tation of assessments and interventions.
Assessments
Assessments will occur at baseline, and at 12 weeks after
the commencement of the intervention. All assessments
will be undertaken by therapists blinded to group allo-
cation. Any inadvertent unblinding of assessors will be
reported.
Primary outcome
The primary outcome measure is muscle cross-sectional
area of the thigh and calf at 12 weeks
Magnetic resonance images of the leg and thigh will be
collected with a 1.5-Tesla magnet. Fifteen transaxial im-
ages, 1 cm thick and spaced 0.5 cm apart will be taken
from the knee joint to the ankle joint (leg) and from the
hip joint to the knee joint (thigh) using a whole-body coil.
Markings on the mid-leg and mid-thigh aligned with
cross-hairs on the imager will allow for similar positioning
during repeat scans. The participants’ feet will be strapped
to a brace to maintain the ankle joint at approximately 90°
and the knee and hip joints extended. Participants will
wear anti-embolism stockings for 30 minutes prior to im-
aging to minimise fluid shifts in the leg.
Secondary outcome measures
To control for sources of pre-analytical variability, partici-
pants will be required to fast for 8 hours before blood is
drawn between 0800 and 0900 hours (35 ml per sample).
Serum samples will be collected at baseline, 1, 2, 3, 4, 8
and 12 weeks (end of intervention). All samples will be
separated and stored at ─20°C until assayed in a central
laboratory, and will be destroyed using standard labora-
tory techniques after the completion of the study.
Serum sclerostin
Serum sclerostin will be measured using ELISA incorp-
orating a biotinylated antibody/horseradish peroxidase-
streptavidin for detection of the analyte. The detection
limit of the sclerostin ELISA is 0.18mg.mL−1 and the
intra-assay coefficient of variability (CV) is between 6
to 10% [33].
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The bone biomarkers N-propeptide of type I procollagen
(P1NP) and β-isomerised C-terminal telopeptide of
collagen type I (β-CTX) will be measured using the
electrochemiluminescence sandwich immunoassays (both
Elecsys 1010 Analytics, Roche Diagnostics, Mannheim,
Germany).
The total P1NP assay detects the monomer and tri-
meric forms of the molecule represented in the serum.
The reference standards given by the manufacturer for
this assay (imprecision 1.8 to 2.9%) independently were
validated (1.4 to 2.3%) ([34]. The inter-assay CVs are 1.4%,
1.7% and 2.0% at 74 μg.L−1, 508 μg.L−1 and 978 μg.L−1, and
intra-assay CVs are 2.0% and 2.3% at 47 μg.L−1 and
643 μg.L−1 [34].
The monoclonal antibodies used in the Elecysis B-Cross
Laps assay recognise all fragments of the β-δAA octa-
peptide of type 1 collagen. Intra-assay precision (CVs)
given by the manufacturer is 4.6%, 1.8% and 1.0% at 0.08
ng.mL−1, 0.39 ng.mL−1 and 3.58 ng.mL−1. Total precision
(CV) is 4.7%. 4.3% and 1.6% at 0.08 ng.mL−1, 0.39 ng.mL−1
and 3.58 ng.mL−1 respectively.
Biomarkers of immune function (systemic low-level
inflammation), which also are myokines, will be assessed
using a MILLIPLEX MAP Human Cytokine/Chemokine
Magnetic Bead Panel Immunology Multiplex Assay read
with a Luminex xMAP® platform (Merck Millipore,
Darmstadt, Germany) in a magnetic bead format for the
determination (pg.ml−1) of: IL-1β, IL-6, IL-10, IL-15,
INF-γ, fibroblast growth factor 2 (FGF2), CX3CL1
(fractalkine), CCL2 (monocyte chemotactic protein-1:
MCP-1), TNF-α, vascular endothelial derived growth
factor (VEGF) and brain-derived neurotrophic factor
(BDNF). Precision data given by the manufacturer esti-
mate accuracy as 87 to 107%. Intra-assay and inter-assay
CVs are given as 2 to 13% and 5 to 19%, respectively.
Muscle mass
Muscle mass will be determined using standard anthropo-
metric methods (measurement of lower limb girths and
skinfold thickness) [35] according to the International
Society for the Advancement of Kinanthropometry (ISAK)
standards. The intraobserver reliability of anthropomentry
is high (R > 0.9) [36].
ISNCSCI motor and sensory scores
Motor and sensory recovery will be measured using the
International Standard for Neurological Classification of
Spinal Cord Injury (ISNCSCI) [37]. The motor score is
derived from testing strength of five key upper limb and
five key lower limb muscles bilaterally with the subject
positioned in the supine position (for example, elbow
flexors, wrist extensors, hip flexors, quadriceps, dorsi-
flexors) on a scale of 0 = no contraction to 5 = normalresistance through full range of motion. Scores are
summed to give a total possible score of 50 for the
upper extremities and 50 for the lower extremities. The
sensory test involves testing pin-prick and light-touch
sensation at key points representing each dermatome.
Pin-prick and light-touch sensation of each dermatome
are separately scored on a 3-point scale (0, 1 and 2).
Scores will be summed to give a total possible score of
224, where a higher score indicates better sensation than a
lower score. The total ISNCSCI motor, light-touch and
pin-prick scores are highly reliable when assessed by expe-
rienced examiners [38].
This assessment will be used during the baseline visit to
confirm the participant’s motor, sensory and neurological
levels as well as the AIS classification, which indicates the
degree of completeness of the spinal cord lesion prior to
randomisation and then again at the post-intervention
assessment.Depression
Depression will be measured using the Hospital Anxiety
and Depression Scale (HADS) [39], which has been found
to be valid [40] and reliable [41] for people with SCI.Assessment of Quality of Life (AQoL-8)
The AQoL-8 is a multi-attribute utility instrument. It will
be used to evaluate whether the study intervention im-
proves participants’ quality of life as well as for an eco-
nomic evaluation of the intervention’s cost-effectiveness.
The AQoL-8 is a self-administered 8-item questionnaire
[42] with excellent test-retest reliability [43].Health Utilities Index Mark 3 (HUI-3)
HUI-3 is a measure of health-related quality of life
widely used in population health surveys, clinical studies
and cost-utility analyses. HUI-3 includes eight attributes
(vision, hearing, speech, ambulation, dexterity, emotion,
cognition and pain), with five or six levels for each attri-
bute. HUI-3 is reliable [44] and is able to discriminate
various aspects of burden associated with chronic condi-
tions as well as describing the differences in overall
health-related quality of life levels [45].WHOQoL-Bref
The WHOQoL-Bref questionnaire was designed by
an international collaboration on quality of life by the
World Health Organisation. It contains 26 questions
about many different aspects of quality of life, with some
additional questions about the person and his/her health.
It has good test-retest reliability [46] and has been found
to be a valid measure in people with SCI [47].
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Sample size
The power analysis is for a one-way fixed effects analysis
of covariance (ANCOVA) with two levels that corres-
pond to FES cycling and passive cycling arms of the
study. This analysis includes baseline value of muscle
CSA in the thigh and calf as a covariate, and uses the
value of muscle CSA in the thigh and calf at week 12 as
the primary outcome. Based on available pilot data [17],
the participants in the passive cycling arm are likely to
lose around 33% of the baseline muscle CSA (mean = 75,
SD = 20) over a period of 12 weeks after SCI (measured
using MRI). Assuming this loss could be contained to 10%
by the proposed FES cycling intervention, thus resulting
in mean changes of 25 (SD = 20) and 7.5 (SD = 20) for
passive cycling and FES cycling respectively, the total
sample size of 42 patients equally distributed between
FES cycling and passive cycling arms will yield power of
0.8 to reject the null hypothesis at 0.05 level of signifi-
cance. The ANCOVA is conservative (that is assuming
no correlation between the baseline and follow-up mea-
sures) and non-directional (that is two-tailed) which
means that an effect in either direction will be inter-
preted. Allowing for a15% drop-out rate, the final sam-
ple size for this study is calculated to be 50 patients
equally distributed between FES cycling and passive
cycling arms.
Statistical analysis
The primary and secondary endpoint analyses will be
conducted on an intention-to-treat basis. Baseline
comparisons between the 2 arms of the study will be
made using means or medians and proportions with
95% confidence intervals. All endpoints and analyses
have been prospectively categorised as either primary
or secondary. Differences in both primary and sec-
ondary endpoints between the 2 arms of the study
will be tested independently at the 0.05 level of sig-
nificance, using a one-way ANCOVA model that will
include the baseline value of a given outcome in question
as a covariate. No formal adjustments will be undertaken
to constrain the overall type I error associated with the
secondary analyses. Their purpose is to supplement evi-
dence from the confirmatory primary analysis to help
more fully characterise the treatment effect. Results
from the secondary analyses will be interpreted in this
context.
Additional exploratory analyses of the effects of strati-
fication factors on the differences in both primary and
secondary endpoints between the two arms of the study
will be undertaken by either explicitly including these
factors into the model (injury status) or by treating them
as random effects in a random-effect regression model
(study sites).Data integrity and management
Data will be stored electronically on a database with se-
cured and restricted access. Data transfer will be encrypted
and any information capable of identifying individuals
removed.
Withdrawals
A participant will be considered to have withdrawn from
the trial when consent is revoked or if the participant
cannot be contacted or located. If this occurs, no further
assessments will be performed. Participants will not be
withdrawn from the trial for protocol violations.
Monitoring
The trial will be overseen and monitored by a Programme
Manager. The Programme Manager will visit each site
to examine trial procedures, ensure data quality and
monitor compliance with the trial protocol. All adverse
events and serious adverse events will be recorded ac-
cording to standard procedures. An interim safety ana-
lysis is planned when 25 participants have completed
their post-intervention assessment. It will be done by an
independent Data Safety Monitoring Board (DSMB)
comprising a statistician and two rehabilitation doctors.
If there are concerns about the safety of participants,
this board will make a recommendation to the trial steer-
ing committee about continuing, stopping, or modifying
the trial.
Discussion
This trial will provide information about the relative
effectiveness of FES-assisted cycling versus passive
cycling in preventing muscle atrophy. This is important
because muscle atrophy is associated with blood vessel
atrophy [48] and predisposes to the development of pres-
sure ulcers. The mechanisms by which active and passive
exercise programmes improve function after SCI also need
to be better understood because they allow for develop-
ment of new and more effective therapeutic strategies. In
this study, the control intervention is not standard care
but an active intervention, involving passive cycling. This
ensures that the intensity of both exercise programmes is
similar, so that the effects of active exercise of the paral-
ysed lower limbs can be identified over and above passive
movement of the limbs.
This trial will adhere to key methodological principles
important for minimising bias (International Conference
on Harmonisation Good Clinical Practice annotated by
the Therapeutic Goods Administration of Australia) [49]
and will be reported according to the CONSORT guide-
lines [50]. For example, allocation will be concealed and
randomised, assessors will be blinded and analyses will
be performed on an intention-to-treat basis. Therapists
and participants will not be blinded due to the nature of
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secondary outcomes will be used. The primary outcome
is a measure of muscle CSA. The secondary outcomes
include measures of a biomarker for disuse osteoporosis,
body composition, neurological function, and quality of
life. Importantly, all adverse events will be rigorously
documented, so that the safety of the interventions can
be evaluated. It is anticipated that this trial will take
24 months to complete.
Trial status
Recruitment commenced in October 2012. Recruitment
continued until 31 May 2014.
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